Despite the development of novel therapeutic strategies, cardiovascular diseases remain the main cause of morbidity and mortality worldwide. Many phase 1 and 2 clinical trials have reported the safety, feasibility and promising potential of stem cell transplantation, however, the optimal cell types, timing of infusion, cell dosage and routes of administration remain to be determined. This paper reviews the findings of various clinical studies and discusses the challenges facing the delivery of stem cell therapy in cardiovascular diseases.
Introduction
Multiple cardiovascular risk factors, such as age, smoking and high blood pressure, can induce ischaemia and myocardial loss, eventually leading to myocardial infarction or heart failure. Stem cell therapy is a novel and promising strategy for regenerative medicine in a variety of diseases. The mechanism of stem cell activity in cardiovascular repair is not understood in detail, but crucial aspects of this process are believed to include the transdifferentiation of stem cells into endothelial cells, smooth muscle cells or cardiomyocytes and the secretion of cytokines from stem cells. 1 The main obstacles to the success of stem cell transplantation in the treatment of cardiovascular diseases are low numbers of circulating stem cells and inadequate homing of the cells. It has been shown that in vivo infusion will increase the number of stem cells in the target organ, thereby providing an attractive therapeutic protocol for tissue repair. 2 Phase 3 trials are required for a conclusive evaluation of stem cell therapy and to identify appropriate indications, and they are also necessary to determine the optimum cell types and transplantation procedures. 3 A computer-based online search of the PubMed database using the key words 'stem cell' and 'heart' returned 277 papers that were related to stem cell trials in cardiovascular diseases. Papers that we regarded as relevant were selected from these for discussion in this review. Previous studies have also revealed a positive effect of stem cell transplantation on heart function, 6-min walk distance and mortality in patients with dilated cardiomyopathy and idiopathic pulmonary arterial hypertension. 8 -11 Lenk et al. 12 injected circulating bloodderived progenitor cells into arteries of patients with peripheral arterial occlusive disease, and preliminary results indicated that this treatment could improve both functional and clinical indices without surgical or other interventional treatment.
Autologous versus allogeneic stem cells
Although the difficulty of obtaining adequate cell numbers and the invasiveness of the procedure necessary to obtain them are recognized, autologous adult stem cells are reported to be preferred in nearly all trials that have been completed in order to avoid possible transplant rejection.
Allogeneic grafting with mesenchymal stem cells (MSCs), which lack major histocompatibility complex antigens and various costimulatory cell surface antigens, was shown to be effective in pigs. 13 In addition, in 2009 a randomized, doubleblind, placebo-controlled, dose-escalation study tested the effects of MSCs in patients with acute myocardial infarction and found that intravenous or intramyocardial infusion of allogeneic MSCs increased LVEF and reduced ventricular tachycardia, with no more adverse events than in placebo-treated patients. 14 Another study concluded that direct myocardial implantation of human fetal-derived stem cells was feasible and improved cardiac function in patients with heart failure. 10 These findings indicate that more trials need to be performed with allogeneic stem cells for further evaluation of their safety and feasibility in heart diseases. Cardiomyocytes have traditionally been regarded as terminally differentiated cells that adapt to increased work and compensate for disease exclusively by hypertrophy. Several types of resident cardiac stem cells (rCSCs) have been identified, based on the expression of some stem cell-related antigens (c-kit, Sca-1, Flk-1 and islet-1) and multiple differentiation into endothelial cells, smooth muscle cells and cardiomyocytes. 24 Initial results of a recent randomized phase 1 trial suggest that intracoronary infusion of autologous c-kit + rCSCs is effective in improving left ventricular systolic function and in reducing infarct size after myocardial infarction, thus indicating c-kit + rCSCs as a prospective candidate for myocardial infarction therapy.
Stem cell sources and types
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Administration routes
Multiple options for stem cell infusion have been explored in the settings of different cardiovascular diseases and therapeutic strategies. Intracoronary infusion of stem cells into an infarction-related vessel is the most commonly used method of administration during coronary interventional procedures. 6 -8, 16 -18,20,21 A novel approach, however, to bone marrow stem cell transplantation in myocardial infarction patients via a noninfarct-related artery has also been reported, and this appears to be safe and to improve cardiac function and myocardial perfusion. 26 On the other hand, intramyocardial 13, 15, 23 or graft vessel 27 injection are preferred for transplanting stem cells into the target zone, especially for patients receiving a coronary artery bypass graft. In addition, subepicardial, 28 transendocardial, 29 intraarterial 12 and intravenous infusions 14 have been shown to be feasible and effective options for treating ischaemic cardiomyopathy, dilated cardiomyopathy and heart failure. Combined intracoronary and intramyocardial administration of BMMCs has also proved effective for acute myocardial infarction. 30 The safety and feasibility of percutaneous retrograde coronary sinus delivery was evaluated recently in patients with chronic refractory angina. 22 The initial findings demonstrated that transplantation of BMMCs and CD34 + cells reduced angina and improved myocardial perfusion, indicating a novel route for future application.
Cell dosage
A standardized dosage for stem cell transplantation is yet to be established. Normally, doses have depended on the source and type of stem cells. For BMMCs, which are usually collected by mobilization of granulocyte colony-stimulating factor, a dose of 10 8 cells is commonly used. 25 The cell doses that have so far been used in most trials are much lower than those used in preclinical studies, in terms of the ratio of weight/dosing, and may explain why clinical outcomes have failed to match 
Infusion timing
The infusion of stem cells should occur during a period that will provide optimal therapeutic outcome but, because of the protracted pathological course of chronic cardiovascular diseases, there is no established time window for infusion. Ischaemic events can lead to immediate local inflammatory responses, the release of cytotoxic substances and subsequent scar formation. In order to keep injected cells viable and integrated within the local microenvironment, a favourable time for stem cell infusion appears to be during the first month after acute myocardial infarction or about 7 -10 days after percutaneous coronary intervention. 26,33 -35 Clinical evidence regarding the optimal timing of cell application is still insufficient. Improving the monitoring of cell infusion and survival by magnetic resonance imaging may be a beneficial approach. 36 
Safety
Although the safety and feasibility of stem cell therapy have been confirmed in a number of trials, several adverse events have been reported. Transient increases in the level of troponin I and in reversible arrhythmias (right bundle branch blockage and atrial fibrillation) have been observed after BMMC transplantation in severe dilated cardiomyopathy. 9 Another study indicated that early intracoronary administration of haematopoietic BMMCs in patients with previous myocardial infarction was associated with accelerated luminal loss and reduced conductance of the infarct-related artery. 18 Manginas et al. 19 
